Department of Hepatobiliary and Pancreatic Surgery, The First Hospital of Jilin University, Changchun, Jilin, P.R. China.
Department of Hand and Foot surgery, The First Hospital of Jilin University, Changchun, Jilin, P.R. China.
PLoS One. 2019 Jan 29;14(1):e0211291. doi: 10.1371/journal.pone.0211291. eCollection 2019.
FAM64A, a marker of cell proliferation, has been investigated as a potential biomarker in several cancers. In the present study, we examined the value of FAM64A expression in the diagnosis and prognosis of pancreatic cancer through bioinformatics analysis of data obtained from The Cancer Genome Atlas (TCGA) database. The diagnostic value of FAM64A expression in pancreatic cancer tissue was deteremined through receiver operating characteristic (ROC) curve analysis, and based on the obtained cut-off value, patients were divided into two groups (high FAM64A expression and low FAM64A expression). Chi-square and Fisher exact tests were applied to identify associations between FAM64A expression and clinical features. Moreover, the effect of FAM64A expression in the survival of pancreatic cancer patients was observed by Kaplan-Meier and Cox analyses. Gene set enrichment analysis (GSEA) was performed using the TCGA dataset. Our results showed that high FAM64A expression in pancreatic cancer was associated with survival status, overall survival (OS), and recurrence. The area under the ROC curve was 0.736, which indicated modest diagnostic value. Patients with higher FAM64A expression had significantly shorter OS and recurrence-free survival (RFS) times. Multivariate survival analysis demonstrated that high FAM64A expression was an independent risk factor for OS and RFS. GSEA identified mitotic spindles, myc targets, MTORC1 signaling, G2M checkpoint, E2F targets, DNA repair, glycolysis and unfolded protein response as differentially enriched with the high FAM64A expression phenotype. In conclusion, high FAM64A mRNA expression is an independent risk factor for poor prognosis in pancreatic cancer.
FAM64A 是细胞增殖的标志物，已在多种癌症中被研究为潜在的生物标志物。在本研究中，我们通过对癌症基因组图谱 (TCGA) 数据库获得的数据进行生物信息学分析，研究了 FAM64A 表达在胰腺癌诊断和预后中的价值。通过接受者操作特征 (ROC) 曲线分析确定 FAM64A 表达在胰腺癌组织中的诊断价值，并根据获得的截断值将患者分为两组（FAM64A 高表达和低表达）。卡方和 Fisher 精确检验用于鉴定 FAM64A 表达与临床特征之间的关联。此外，通过 Kaplan-Meier 和 Cox 分析观察 FAM64A 表达对胰腺癌患者生存的影响。使用 TCGA 数据集进行基因集富集分析 (GSEA)。我们的结果表明，胰腺癌中 FAM64A 的高表达与生存状态、总生存期 (OS) 和复发有关。ROC 曲线下面积为 0.736，表明诊断价值中等。FAM64A 表达较高的患者 OS 和无复发生存 (RFS) 时间明显缩短。多变量生存分析表明，FAM64A 高表达是 OS 和 RFS 的独立危险因素。GSEA 确定了有丝分裂纺锤体、myc 靶点、MTORC1 信号、G2M 检查点、E2F 靶点、DNA 修复、糖酵解和未折叠蛋白反应与高 FAM64A 表达表型差异富集。总之，FAM64A mRNA 表达是胰腺癌预后不良的独立危险因素。
